Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Noopur Raje, MD, Parameswaran N. Hari, MD, MRCP, MS, Heather Landau, MD, Paul G. Richardson, MD, Jacalyn Rosenblatt, MD, Nicole Couture, RN, John F. Lyons, PhD, Gillian Langford, PhD, Murray Yule, MD

Blood (2013) 122 (21): 1976.

https://doi.org/10.1182/blood.V122.21.1976.1976

Published: 2013

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Loredana Santo, M.D., Teru Hideshima, MD., Ph.D., Erik A. Nelson, Ph.D, Diana Cirstea, MD, Madhavi Bandi, Ph.D, Hiroshi Ikeda, MD, PhD, Gullu Gorgun, PhD, Sonia Vallet, MD., Samantha Pozzi, MD, Giulia Perrone, MD, Kishan Patel, Yiguo Hu, Ph.D, Matthew S Squires, Murray Yule, Elisabetta Calabrese, MD., Dharminder Chauhan, Ph.D, Nikhil C. Munshi, Kenneth C. Anderson, MD, Noopur Raje, MD.

Blood (2009) 114 (22): 3833.

https://doi.org/10.1182/blood.V114.22.3833.3833

Published: 2009

Journal Articles

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

John F Lyons, PhD, Matthew S Squires, John Goodall, Murray Yule, Farhad Ravandi, MD, James Foran, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4159.

https://doi.org/10.1182/blood.V114.22.4159.4159

Published: 2009

Journal Articles

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Vicky Lock, Laurence Cooke, Murray Yule, Neil T Thompson, K. Della Croce, John F Lyons, Matthew S Squires, Daruka Mahadevan

Blood (2008) 112 (11): 3161.

https://doi.org/10.1182/blood.V112.11.3161.3161

Published: 2008

Journal Articles

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

Matthew S. Squires, PhD, Ruth E. Feltell, BSc, Victoria Lock, Donna M. Smith, PhD, Jon E. Lewis, Jacqueline Higgins, Murray Yule, MD, Neil T. Thompson, PhD, Laurence Cooke, Kimiko D. Croce, Wenqing Qi, John F. Lyons, PhD, Daruka Mahadevan

Blood (2007) 110 (11): 3127.

https://doi.org/10.1182/blood.V110.11.3127.3127

Published: 2007

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

NARROW

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only